| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 28 | 2022 | 75 | 2.340 |
Why?
|
| Prenatal Exposure Delayed Effects | 26 | 2019 | 206 | 1.960 |
Why?
|
| Multiple Sclerosis | 16 | 2019 | 98 | 1.600 |
Why?
|
| Bipolar Disorder | 9 | 2022 | 57 | 1.570 |
Why?
|
| Polymorphism, Single Nucleotide | 27 | 2020 | 305 | 1.430 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2022 | 319 | 1.420 |
Why?
|
| Phenytoin | 2 | 2020 | 4 | 1.240 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2020 | 5 | 1.240 |
Why?
|
| Genome-Wide Association Study | 23 | 2022 | 209 | 1.130 |
Why?
|
| Humans | 94 | 2022 | 16832 | 0.860 |
Why?
|
| Male | 66 | 2020 | 9556 | 0.810 |
Why?
|
| Female | 74 | 2020 | 12193 | 0.810 |
Why?
|
| Cognition Disorders | 3 | 2014 | 30 | 0.790 |
Why?
|
| Pharmacogenomic Variants | 2 | 2020 | 8 | 0.760 |
Why?
|
| Genetic Loci | 8 | 2020 | 41 | 0.760 |
Why?
|
| Adult | 59 | 2020 | 7255 | 0.760 |
Why?
|
| Risk Factors | 37 | 2020 | 3108 | 0.720 |
Why?
|
| HLA-DRB1 Chains | 8 | 2019 | 12 | 0.670 |
Why?
|
| Pregnancy | 33 | 2019 | 1555 | 0.650 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 4 | 0.630 |
Why?
|
| Drug Eruptions | 1 | 2020 | 4 | 0.630 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 196 | 0.620 |
Why?
|
| Cohort Studies | 33 | 2020 | 2396 | 0.580 |
Why?
|
| Middle Aged | 34 | 2020 | 7515 | 0.560 |
Why?
|
| Body Mass Index | 9 | 2018 | 925 | 0.540 |
Why?
|
| Child of Impaired Parents | 5 | 2013 | 27 | 0.530 |
Why?
|
| Ethnic Groups | 10 | 2020 | 418 | 0.520 |
Why?
|
| Case-Control Studies | 21 | 2018 | 995 | 0.500 |
Why?
|
| Pregnancy Complications, Infectious | 8 | 2016 | 158 | 0.480 |
Why?
|
| Toxoplasmosis | 3 | 2016 | 4 | 0.470 |
Why?
|
| European Continental Ancestry Group | 12 | 2020 | 400 | 0.470 |
Why?
|
| Aged | 25 | 2020 | 5901 | 0.460 |
Why?
|
| Paternal Age | 3 | 2013 | 9 | 0.460 |
Why?
|
| Influenza, Human | 5 | 2016 | 292 | 0.450 |
Why?
|
| Oxytocics | 1 | 2014 | 2 | 0.430 |
Why?
|
| Oxytocin | 1 | 2014 | 4 | 0.430 |
Why?
|
| Glaucoma | 3 | 2020 | 11 | 0.400 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1887 | 0.390 |
Why?
|
| Smoking | 4 | 2017 | 373 | 0.380 |
Why?
|
| Pregnancy Complications | 3 | 2012 | 202 | 0.370 |
Why?
|
| Young Adult | 15 | 2019 | 2456 | 0.360 |
Why?
|
| Depressive Disorder, Major | 2 | 2018 | 95 | 0.350 |
Why?
|
| Aging | 4 | 2016 | 146 | 0.340 |
Why?
|
| Multifactorial Inheritance | 3 | 2020 | 19 | 0.340 |
Why?
|
| Health | 3 | 2015 | 26 | 0.340 |
Why?
|
| Alleles | 7 | 2020 | 59 | 0.330 |
Why?
|
| Prospective Studies | 12 | 2014 | 1186 | 0.310 |
Why?
|
| Pharmacogenomic Testing | 2 | 2020 | 4 | 0.310 |
Why?
|
| Hispanic Americans | 5 | 2020 | 350 | 0.310 |
Why?
|
| Communicable Diseases | 1 | 2009 | 14 | 0.290 |
Why?
|
| Septum Pellucidum | 1 | 2009 | 1 | 0.290 |
Why?
|
| Genomics | 4 | 2020 | 54 | 0.280 |
Why?
|
| Immunoglobulin G | 5 | 2016 | 33 | 0.280 |
Why?
|
| Mutation | 4 | 2018 | 86 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2020 | 2463 | 0.280 |
Why?
|
| Maternal Exposure | 6 | 2016 | 84 | 0.270 |
Why?
|
| Genotype | 10 | 2017 | 198 | 0.270 |
Why?
|
| Computational Biology | 3 | 2020 | 20 | 0.270 |
Why?
|
| Adolescent | 17 | 2019 | 3464 | 0.260 |
Why?
|
| Blood Pressure | 2 | 2020 | 278 | 0.250 |
Why?
|
| Electronic Health Records | 4 | 2022 | 702 | 0.240 |
Why?
|
| Molecular Epidemiology | 4 | 2020 | 33 | 0.240 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2005 | 2 | 0.230 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2014 | 21 | 0.230 |
Why?
|
| Quantitative Trait Loci | 3 | 2020 | 29 | 0.230 |
Why?
|
| Macular Degeneration | 2 | 2016 | 14 | 0.230 |
Why?
|
| Social Class | 2 | 2017 | 106 | 0.230 |
Why?
|
| Genotyping Techniques | 2 | 2015 | 24 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1098 | 0.220 |
Why?
|
| Cognition | 2 | 2016 | 90 | 0.210 |
Why?
|
| HLA-A2 Antigen | 2 | 2014 | 2 | 0.210 |
Why?
|
| California | 13 | 2019 | 2244 | 0.210 |
Why?
|
| Intraocular Pressure | 3 | 2018 | 9 | 0.200 |
Why?
|
| Risk Assessment | 5 | 2020 | 1047 | 0.190 |
Why?
|
| Phenotype | 6 | 2019 | 105 | 0.190 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2017 | 69 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2019 | 15 | 0.180 |
Why?
|
| Toxoplasma | 2 | 2016 | 3 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 110 | 0.170 |
Why?
|
| Adult Children | 2 | 2012 | 8 | 0.170 |
Why?
|
| African Americans | 5 | 2019 | 394 | 0.170 |
Why?
|
| Genetic Background | 1 | 2020 | 2 | 0.170 |
Why?
|
| Skin Pigmentation | 1 | 2020 | 6 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 1 | 0.160 |
Why?
|
| Breast Density | 1 | 2020 | 24 | 0.160 |
Why?
|
| Cornea | 1 | 2020 | 2 | 0.160 |
Why?
|
| Corneal Diseases | 1 | 2020 | 2 | 0.160 |
Why?
|
| HLA-B15 Antigen | 1 | 2020 | 2 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 155 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 55 | 0.160 |
Why?
|
| Age Factors | 5 | 2014 | 814 | 0.160 |
Why?
|
| Maternal Welfare | 1 | 2000 | 11 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 59 | 0.150 |
Why?
|
| Exome | 2 | 2022 | 14 | 0.150 |
Why?
|
| HLA-A Antigens | 2 | 2017 | 2 | 0.150 |
Why?
|
| Pregnancy Trimesters | 3 | 2016 | 27 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2020 | 51 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2019 | 17 | 0.150 |
Why?
|
| Fetal Development | 1 | 2019 | 15 | 0.150 |
Why?
|
| Sweden | 5 | 2017 | 17 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2019 | 17 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 4 | 2020 | 24 | 0.140 |
Why?
|
| Child | 6 | 2019 | 2433 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 130 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 913 | 0.140 |
Why?
|
| Sex Factors | 5 | 2019 | 560 | 0.140 |
Why?
|
| Intelligence Tests | 2 | 2016 | 3 | 0.140 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2018 | 7 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 12 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 18 | 0.130 |
Why?
|
| Behavior | 1 | 2017 | 14 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 19 | 0.130 |
Why?
|
| Genetic Variation | 4 | 2017 | 67 | 0.130 |
Why?
|
| Anthropometry | 1 | 2017 | 54 | 0.130 |
Why?
|
| Datasets as Topic | 1 | 2017 | 17 | 0.130 |
Why?
|
| Interleukin-8 | 2 | 2010 | 4 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2018 | 120 | 0.130 |
Why?
|
| Prevalence | 7 | 2016 | 785 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 290 | 0.130 |
Why?
|
| Exonucleases | 1 | 2016 | 1 | 0.120 |
Why?
|
| Presbycusis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 6 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 3 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 235 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2016 | 7 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 64 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 60 | 0.120 |
Why?
|
| Major Histocompatibility Complex | 2 | 2013 | 3 | 0.120 |
Why?
|
| Hearing Loss | 1 | 2016 | 14 | 0.120 |
Why?
|
| Prenatal Care | 2 | 2016 | 123 | 0.120 |
Why?
|
| Vitamin D | 1 | 2017 | 75 | 0.120 |
Why?
|
| Drinking | 1 | 2016 | 3 | 0.120 |
Why?
|
| Coffee | 1 | 2016 | 5 | 0.120 |
Why?
|
| Stress, Psychological | 2 | 2015 | 136 | 0.120 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 2 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2016 | 12 | 0.120 |
Why?
|
| Biomarkers | 5 | 2019 | 284 | 0.110 |
Why?
|
| Refraction, Ocular | 1 | 2015 | 2 | 0.110 |
Why?
|
| Refractive Errors | 1 | 2015 | 7 | 0.110 |
Why?
|
| Bereavement | 1 | 1995 | 8 | 0.110 |
Why?
|
| Pediatric Obesity | 2 | 2014 | 101 | 0.110 |
Why?
|
| Telomere | 1 | 2015 | 16 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2015 | 2 | 0.110 |
Why?
|
| Allopurinol | 1 | 2015 | 2 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 5 | 0.110 |
Why?
|
| Maternal Age | 4 | 2009 | 73 | 0.110 |
Why?
|
| Gout Suppressants | 1 | 2015 | 2 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| Gene Frequency | 4 | 2017 | 26 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 8 | 0.110 |
Why?
|
| Social Environment | 1 | 1995 | 77 | 0.110 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 1 | 0.110 |
Why?
|
| Family | 1 | 2015 | 99 | 0.110 |
Why?
|
| Aquaporin 4 | 1 | 2014 | 2 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 5 | 0.110 |
Why?
|
| Proportional Hazards Models | 6 | 2013 | 657 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 3 | 0.110 |
Why?
|
| Mortality | 1 | 1995 | 116 | 0.110 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2014 | 10 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 298 | 0.110 |
Why?
|
| Psychotic Disorders | 3 | 2011 | 52 | 0.100 |
Why?
|
| Alcoholism | 1 | 2017 | 235 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 1204 | 0.100 |
Why?
|
| Body Size | 1 | 2014 | 27 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 515 | 0.100 |
Why?
|
| Continental Population Groups | 1 | 2015 | 255 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2016 | 828 | 0.100 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2012 | 29 | 0.100 |
Why?
|
| Risk | 4 | 2017 | 453 | 0.090 |
Why?
|
| Poverty | 1 | 2014 | 167 | 0.090 |
Why?
|
| Gene-Environment Interaction | 3 | 2018 | 21 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2010 | 47 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 13 | 0.090 |
Why?
|
| Dementia, Vascular | 1 | 2012 | 5 | 0.090 |
Why?
|
| Vitamin A Deficiency | 1 | 2012 | 3 | 0.090 |
Why?
|
| Haplotypes | 3 | 2019 | 29 | 0.090 |
Why?
|
| Genital Diseases, Female | 2 | 2009 | 7 | 0.090 |
Why?
|
| Hypertension | 1 | 2016 | 475 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 1058 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 107 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antibodies, Protozoan | 2 | 2016 | 3 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 122 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2012 | 51 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 4 | 0.090 |
Why?
|
| Prenatal Diagnosis | 3 | 2010 | 20 | 0.080 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2011 | 2 | 0.080 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 6 | 0.080 |
Why?
|
| Bariatric Surgery | 1 | 2013 | 134 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 1 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2010 | 5 | 0.080 |
Why?
|
| Brain | 1 | 2010 | 47 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 346 | 0.070 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2007 | 12 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Somatomedins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 6 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 2 | 2020 | 23 | 0.070 |
Why?
|
| Infant | 4 | 2016 | 1212 | 0.070 |
Why?
|
| Genome, Human | 3 | 2014 | 24 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 4 | 2014 | 18 | 0.070 |
Why?
|
| Craniofacial Abnormalities | 1 | 2008 | 2 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 15 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 36 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 989 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 811 | 0.070 |
Why?
|
| Gene Expression | 2 | 2018 | 15 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 479 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2006 | 70 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2020 | 29 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 410 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.060 |
Why?
|
| Logistic Models | 3 | 2014 | 796 | 0.060 |
Why?
|
| Research Design | 4 | 2016 | 319 | 0.060 |
Why?
|
| Homocysteine | 1 | 2007 | 11 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2006 | 3 | 0.060 |
Why?
|
| Herpes Simplex | 1 | 2006 | 7 | 0.060 |
Why?
|
| Animals | 3 | 2018 | 237 | 0.060 |
Why?
|
| Pregnancy, Unwanted | 1 | 2006 | 7 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2016 | 1430 | 0.060 |
Why?
|
| Blood Group Incompatibility | 1 | 2005 | 1 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2014 | 569 | 0.060 |
Why?
|
| Protective Factors | 2 | 2016 | 28 | 0.060 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2016 | 23 | 0.050 |
Why?
|
| State Health Plans | 1 | 2005 | 30 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 23 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 568 | 0.050 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 1 | 0.050 |
Why?
|
| Chromosome Mapping | 2 | 2013 | 15 | 0.050 |
Why?
|
| Depression, Postpartum | 1 | 2004 | 27 | 0.050 |
Why?
|
| Cytokines | 2 | 2016 | 28 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 3 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 154 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 45 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 29 | 0.050 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 6 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2016 | 24 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 10 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 3 | 0.040 |
Why?
|
| United States | 3 | 2017 | 3858 | 0.040 |
Why?
|
| Educational Status | 2 | 2006 | 163 | 0.040 |
Why?
|
| Aorta | 1 | 2020 | 2 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 8 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2020 | 3 | 0.040 |
Why?
|
| Chromatin | 1 | 2020 | 5 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 20 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 353 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 51 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 100 | 0.040 |
Why?
|
| Incidence | 3 | 2015 | 1229 | 0.040 |
Why?
|
| Mammography | 1 | 2020 | 141 | 0.040 |
Why?
|
| Binding Sites | 1 | 2019 | 2 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 7 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2000 | 58 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2019 | 29 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 27 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1233 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 2 | 0.030 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2018 | 2 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 3 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 4 | 0.030 |
Why?
|
| Pesticides | 1 | 2018 | 8 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 16 | 0.030 |
Why?
|
| Proteins | 1 | 2018 | 13 | 0.030 |
Why?
|
| United Kingdom | 1 | 2018 | 24 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 59 | 0.030 |
Why?
|
| Asian Americans | 1 | 2019 | 146 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 60 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 3 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2017 | 4 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 197 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 66 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 23 | 0.030 |
Why?
|
| Eating | 1 | 1996 | 35 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 47 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 32 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2017 | 117 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 1996 | 6 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1996 | 15 | 0.030 |
Why?
|
| Work | 1 | 2015 | 10 | 0.030 |
Why?
|
| Mothers | 2 | 2007 | 104 | 0.030 |
Why?
|
| Genetic Testing | 1 | 1996 | 63 | 0.030 |
Why?
|
| Comorbidity | 2 | 2008 | 516 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 248 | 0.030 |
Why?
|
| Pregnant Women | 1 | 1996 | 41 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 6 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 21 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 5 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 27 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 22 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 37 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 61 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 1996 | 140 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2015 | 2 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 8 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 58 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2016 | 275 | 0.030 |
Why?
|
| Weight Gain | 1 | 1996 | 167 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 18 | 0.030 |
Why?
|
| Optic Neuritis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Myelitis, Transverse | 1 | 2014 | 4 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2014 | 1 | 0.030 |
Why?
|
| Arabidopsis Proteins | 1 | 2014 | 1 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 2 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 653 | 0.030 |
Why?
|
| HLA-DP beta-Chains | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 2 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 6 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 8 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2013 | 10 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2013 | 11 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 26 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 118 | 0.020 |
Why?
|
| Mental Disorders | 2 | 2006 | 248 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 18 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 4 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 1 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 27 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 40 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 120 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 129 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 175 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 210 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 8 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 256 | 0.020 |
Why?
|
| Life Change Events | 1 | 2010 | 26 | 0.020 |
Why?
|
| Health Behavior | 1 | 2012 | 332 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 210 | 0.020 |
Why?
|
| Bias | 2 | 2000 | 90 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 53 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 489 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 3 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Hemoglobinometry | 1 | 2008 | 3 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 30 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2008 | 16 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2008 | 55 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 222 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2004 | 352 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 816 | 0.020 |
Why?
|
| Informatics | 1 | 2007 | 2 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2007 | 11 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 21 | 0.020 |
Why?
|
| Parity | 1 | 2007 | 53 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 66 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 4 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 10 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2007 | 34 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2007 | 22 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 21 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 22 | 0.020 |
Why?
|
| Infection | 1 | 2006 | 17 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 89 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 14 | 0.010 |
Why?
|
| Maternal Behavior | 1 | 2005 | 11 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2007 | 145 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 571 | 0.010 |
Why?
|
| Influenza A virus | 1 | 2004 | 13 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 24 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 64 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 305 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2003 | 8 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 48 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 25 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 305 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2004 | 140 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2004 | 294 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 358 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 447 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 261 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 520 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2002 | 164 | 0.010 |
Why?
|
| Registries | 1 | 2000 | 449 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1996 | 28 | 0.010 |
Why?
|
| Dietary Sucrose | 1 | 1996 | 13 | 0.010 |
Why?
|
| Diet Records | 1 | 1996 | 37 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1996 | 47 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1996 | 88 | 0.010 |
Why?
|
| Energy Intake | 1 | 1996 | 98 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1996 | 4 | 0.010 |
Why?
|
| Linear Models | 1 | 1996 | 187 | 0.010 |
Why?
|
| Comprehension | 1 | 1996 | 19 | 0.010 |
Why?
|